Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804

Q3 FY20 results · Oct–Dec 2019

Aurobindo Pharma reported revenue from operations of ₹5,895.00 crore (up 11.9% from Q3 FY19) and net profit of ₹705.31 crore (down 1.0% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY20	Q3 FY19	YoY	Q2 FY20	QoQ
Revenue from operations	5,895.00	5,269.67	+11.9%	5,600.47	+5.3%
Other income	21.99	63.85	−65.6%	20.62	+6.6%
Total income	5,916.99	5,333.52	+10.9%	5,621.09	+5.3%
Profit before share of associates & JVs and tax	938.81	914.42	+2.7%	863.83	+8.7%
Share of profit/(loss) of associates & JVs	(0.64)	2.57		0.07
Net profit for the period	705.31	712.21	−1.0%	639.53	+10.3%
Attributable to shareholders of the company	705.45	538.77	+30.9%	639.86	+10.3%
EPS, basic (₹)	12.04	12.15	−0.9%	10.92	+10.3%
Net margin (%)	12.0	13.5		11.4

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY20	Q3 FY19	YoY	Q2 FY20	QoQ
Revenue from operations	3,345.67	3,248.10	+3.0%	3,221.66	+3.8%
Other income	16.88	136.87	−87.7%	33.64	−49.8%
Total income	3,362.55	3,384.97	−0.7%	3,255.30	+3.3%
Profit before tax	549.30	584.68	−6.1%	522.06	+5.2%
Net profit for the period	419.07	463.51	−9.6%	398.13	+5.3%
EPS, basic (₹)	7.15	7.91	−9.6%	6.80	+5.1%
Net margin (%)	12.5	14.3		12.4

Consolidated

Filed with BSE: 07 Feb 2020, 12:13 IST
Board meeting: 06 Feb 2020
Period: 01 Oct 2019 to 31 Dec 2019
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 07 Feb 2020, 12:13 IST
Board meeting: 06 Feb 2020
Period: 01 Oct 2019 to 31 Dec 2019
Review status: Unaudited
Source: XBRL filing on BSE